Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
A phase II and biomarker study of an irreversible pan-human EGF receptor (HER) tyrosine kinase inhibitor dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of esophagus.
- Authors
- Kim, HS[Kim, Hyo Song]; Kim, HS[Kim, Han Sang]; Sun, JM[Sun, Jong-Mu]; Ahn, MJ[Ahn, Myung-Ju]; Park, K[Park, Keunchil]; Kim, HG[Kim, Hoon-Gu]; Chung, IJ[Chung, Ik-Joo]; Lee, JS[Lee, Jong-Seok]; Lee, SH[Lee, Se-Hoon]; Lee, KH[Lee, Kyung Hee]; Kim, DJ[Kim, Dae Joon]; Kim, HR[Kim, Hye Ryun]; Kim, JH[Kim, Joo-Hang]; Cho, BC[Cho, Byoung Chul]
- Issue Date
- 20-May-2014
- Publisher
- AMER SOC CLINICAL ONCOLOGY
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.32, no.15
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 32
- Number
- 15
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.